ZTS Market Analysis

Overview

Fundamentals

P/E ratio12.72Forward 11.34
EPS (TTM)$6.106.0% YoY
Profit margin28.0%HEALTHCARE
Market cap$32.53BLarge cap

Wall Street coverage

$124.59median target· current $175.82 (-29.1%)20 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
11.34
PEG ratio
1.86
P/B
10.06
P/S (TTM)
3.41
EV/EBITDA
9.80

Profitability & growth

ROE (TTM)
67.7%
Operating margin
36.6%
Revenue growth YoY
2.9%
Dividend yield
2.7%
Beta
0.86
Last earnings
May 7, 2026 · Estimate $1.54 · Reported $1.42
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Zoetis Inc

Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.

Classification

Exchange
NYSE
Country
USA
Currency
USD

Company profile

HQ
10 SYLVAN WAY, PARSIPPANY, NJ
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$32.53B
Shares outstanding$419.2M
52W high$168.90
52W low$72.38

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer